Real-world effectiveness and safety of esketamine intranasal spray combined with treatment-as-usual in psychiatric inpatients
European Psychiatry August 27, 2024 Erhan Kavakbasi, M. Yilmaz, Ö. Bulut et al.
Introduction Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major depressive disorder (MDD). Real-world data on the effectiveness and safety of esketamine nasal spray in clinical use are limited. Objectives To...